DDrare: Database of Drug Development for Rare Diseases

280. 巨大動静脈奇形（頚部顔面又は四肢病変）
［臨床試験数：22，薬物数：26（DrugBank：13），標的遺伝子数：11，標的パスウェイ数：147］

Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Bevacizumab; Bleomycin; Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Doxycycline; Ethanol; Heparin; Heparin Sodium; L04AA10; Lipiodol; Lipiodol® Ultra Fluid with surgical glues; Lovastatin; Mekinist; Minocycline; Other: normal saline; RAPAMUNE; Rapamune; SIROLIMUS; Sirolimus; Sirolimus 0,1% crème; Sirolimus 1mg/mL; Sufentanil; Thalidomide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003573-26-BE (EUCTR)		18/12/2019	Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care	Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated - TRAMAV	Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Mekinist Product Name: Mekinist	Cliniques universitaires Saint-Luc	NULL	NA			Female: yes Male: yes	20	Phase 2	Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-003573-26-BE
(EUCTR)

18/12/2019

Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care

Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated - TRAMAV

Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Trade Name: Mekinist
Product Name: Mekinist

Cliniques universitaires Saint-Luc

NULL

Female: yes
Male: yes

Phase 2

Belgium